secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001628280-26-018211
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm's Phase 3 EMANATE trial misses primary endpoints; post hoc signals in POMC/SRC1
--------------------------------------------------------------------------------

- Four substudies failed primary endpoint: placebo-adjusted BMI reductions of 4.3% (POMC/PCSK1), 3.6% (LEPR), 4.0% (SRC1), 1.7% (SH2B1); all p>0.05.
- Post hoc LOCF analysis showed significant BMI reductions: POMC/PCSK1 -5.5% (p=0.0010), SRC1 -6.2% (p<0.0001) vs placebo.
- Completer analysis: placebo-adjusted BMI -9.7% (POMC/PCSK1, n=41, p=0.0002) and -8.0% (SRC1, n=29, p=0.0158).
- Safety profile consistent with prior studies; no new signals. Common AEs: skin hyperpigmentation, injection-site reactions.
- Rhythm to evaluate next-gen MC4R agonists bivamelagon and RM-718 for SRC1 and POMC; continuing DAYBREAK exploratory work.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/0001628280-26-018211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/rytm-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-018211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer